Dr Pankaj Dhamija, Hospital Director, Medanta resigns; plans to join competitor
NiveshIQ
NSE: MEDANTA · Healthcare
Global Health Ltd.
₹1,298.40▲ ₹28.10 (+2.21%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on MEDANTA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Global Health Ltd.
Global Health Limited (MEDANTA) operates a diversified network of specialty hospitals and diagnostic centers across India, offering services ranging from advanced cardiac and cancer care to orthopaedics, transplant surgeries, and telemedicine. The company’s revenue of ₹4,683 crore in FY27 was driven by high-margin specialty procedures, with net income of ₹556 crore reflecting efficient cost management and a growing patient base. Recent developments include the issuance of Reg 74(5) depository certificates for Q2 FY27, signaling continued capital market activity and investor confidence. MEDANTA maintains a competitive edge through its flagship Medanta hospitals, renowned for world‑class care and a strong referral network, positioning it ahead of regional peers in the premium healthcare segm
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹3,275 Cr +21.56% | ₹3,692 Cr +12.74% | ₹4,410 Cr +19.44% |
| EBITDA Margin | 24.40% | 23.75% | 20.84% |
| Net Profit | ₹478.19 Cr +46.65% | ₹481.44 Cr +0.68% | ₹556.46 Cr +15.58% |
| EPS | ₹17.80 | ₹17.92 | ₹20.71 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Global Health accepts Dr. Pankaj Dhamija's resignation as Hospital Director
Global Health accepts Dr. Pankaj Dhamija's resignation as Hospital Director
🔒
+ 3 more stories about Global Health Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹1, 304 Cr, PAT ₹159 Cr, EPS ₹5.91, EBITDA margin 22.0%. Growth context: revenue YoY +26.5%, PAT YoY -0.2%, revenue QoQ +12.5%, PAT QoQ +10.2%. Street verdict: beat, revenue surprise +7.8%, PAT surprise +9.4%.
Recent corporate activity highlights new capacity addition and capex deployment and geographic expansion and internation...
FY26 (last completed FY): revenue ₹4, 410 Cr, PAT ₹556 Cr, EBITDA margin 20.8%, EPS ₹20.71. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for MEDANTA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track MEDANTA alongside your other holdings
Unlock full MEDANTA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Global Health Ltd.?
NiveshIQ detects active intelligence signals for Global Health Ltd. (MEDANTA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Global Health Ltd.?
Global Health Ltd. operates in the Healthcare sector with a market capitalisation of ₹3,424,836.6L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.